vs
MESA LABORATORIES INC（MLAB）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是STEM, INC.的1.4倍（$65.1M vs $47.1M），MESA LABORATORIES INC净利率更高（5.6% vs -33.9%，领先39.5%），MESA LABORATORIES INC同比增速更快（3.6% vs -15.6%），过去两年STEM, INC.的营收复合增速更高（36.1% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
MLAB vs STEM — 直观对比
营收规模更大
MLAB
是对方的1.4倍
$47.1M
营收增速更快
MLAB
高出19.2%
-15.6%
净利率更高
MLAB
高出39.5%
-33.9%
两年增速更快
STEM
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $47.1M |
| 净利润 | $3.6M | $-16.0M |
| 毛利率 | 64.2% | 48.9% |
| 营业利润率 | 12.2% | -17.7% |
| 净利率 | 5.6% | -33.9% |
| 营收同比 | 3.6% | -15.6% |
| 净利润同比 | 316.6% | 68.8% |
| 每股收益（稀释后） | $0.65 | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABSTEM
| Q4 25 | $65.1M | $47.1M | ||
| Q3 25 | $60.7M | $38.2M | ||
| Q2 25 | $59.5M | $38.4M | ||
| Q1 25 | $62.1M | $32.5M | ||
| Q4 24 | $62.8M | $55.8M | ||
| Q3 24 | $57.8M | $29.3M | ||
| Q2 24 | $58.2M | $34.0M | ||
| Q1 24 | $58.9M | $25.5M |
净利润MLABSTEM
| Q4 25 | $3.6M | $-16.0M | ||
| Q3 25 | $2.5M | $-23.8M | ||
| Q2 25 | $4.7M | $202.5M | ||
| Q1 25 | $-7.1M | $-25.0M | ||
| Q4 24 | $-1.7M | $-51.1M | ||
| Q3 24 | $3.4M | $-148.3M | ||
| Q2 24 | $3.4M | $-582.3M | ||
| Q1 24 | $-254.6M | $-72.3M |
毛利率MLABSTEM
| Q4 25 | 64.2% | 48.9% | ||
| Q3 25 | 61.5% | 35.5% | ||
| Q2 25 | 62.0% | 33.4% | ||
| Q1 25 | 61.8% | 32.4% | ||
| Q4 24 | 63.3% | -4.4% | ||
| Q3 24 | 61.3% | 21.2% | ||
| Q2 24 | 64.0% | 27.6% | ||
| Q1 24 | 62.1% | -95.0% |
营业利润率MLABSTEM
| Q4 25 | 12.2% | -17.7% | ||
| Q3 25 | 7.8% | -33.6% | ||
| Q2 25 | 5.1% | -34.8% | ||
| Q1 25 | 2.4% | -65.0% | ||
| Q4 24 | 9.2% | -84.4% | ||
| Q3 24 | 6.1% | -493.2% | ||
| Q2 24 | 9.6% | -1705.5% | ||
| Q1 24 | -460.6% | -267.0% |
净利率MLABSTEM
| Q4 25 | 5.6% | -33.9% | ||
| Q3 25 | 4.1% | -62.2% | ||
| Q2 25 | 8.0% | 527.8% | ||
| Q1 25 | -11.4% | -76.9% | ||
| Q4 24 | -2.7% | -91.6% | ||
| Q3 24 | 5.9% | -506.3% | ||
| Q2 24 | 5.8% | -1712.6% | ||
| Q1 24 | -432.2% | -283.9% |
每股收益（稀释后）MLABSTEM
| Q4 25 | $0.65 | $-4.40 | ||
| Q3 25 | $0.45 | $-2.84 | ||
| Q2 25 | $0.85 | $-1.79 | ||
| Q1 25 | $-1.30 | $-0.15 | ||
| Q4 24 | $-0.31 | $-15.29 | ||
| Q3 24 | $0.63 | $-18.24 | ||
| Q2 24 | $0.62 | $-71.81 | ||
| Q1 24 | $-47.26 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $48.9M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $-249.4M |
| 总资产 | $434.8M | $308.9M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABSTEM
| Q4 25 | $29.0M | $48.9M | ||
| Q3 25 | $20.4M | $43.1M | ||
| Q2 25 | $21.3M | $40.8M | ||
| Q1 25 | $27.3M | $58.6M | ||
| Q4 24 | $27.3M | $56.3M | ||
| Q3 24 | $24.3M | $75.4M | ||
| Q2 24 | $28.5M | $89.6M | ||
| Q1 24 | $28.2M | $112.8M |
总债务MLABSTEM
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABSTEM
| Q4 25 | $186.7M | $-249.4M | ||
| Q3 25 | $178.5M | $-235.7M | ||
| Q2 25 | $172.5M | $-214.1M | ||
| Q1 25 | $159.8M | $-417.5M | ||
| Q4 24 | $155.2M | $-398.4M | ||
| Q3 24 | $161.5M | $-344.1M | ||
| Q2 24 | $150.7M | $-203.2M | ||
| Q1 24 | $145.4M | $371.6M |
总资产MLABSTEM
| Q4 25 | $434.8M | $308.9M | ||
| Q3 25 | $430.4M | $362.6M | ||
| Q2 25 | $435.7M | $379.2M | ||
| Q1 25 | $433.3M | $405.1M | ||
| Q4 24 | $433.3M | $437.4M | ||
| Q3 24 | $454.1M | $537.8M | ||
| Q2 24 | $440.4M | $691.5M | ||
| Q1 24 | $446.8M | $1.3B |
负债/权益比MLABSTEM
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABSTEM
| Q4 25 | $18.8M | $8.2M | ||
| Q3 25 | $8.2M | $11.4M | ||
| Q2 25 | $1.9M | $-21.3M | ||
| Q1 25 | $12.7M | $8.5M | ||
| Q4 24 | $18.1M | $-14.7M | ||
| Q3 24 | $5.3M | $-9.4M | ||
| Q2 24 | $10.7M | $-11.9M | ||
| Q1 24 | $12.9M | $-621.0K |
自由现金流MLABSTEM
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
自由现金流率MLABSTEM
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
资本支出强度MLABSTEM
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
现金转化率MLABSTEM
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
STEM
暂无分部数据
